Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
AIDS vaccines: where are we?.

Expert review of clinical pharmacology

Kelleher P.
PMID: 22112252
Expert Rev Clin Pharmacol. 2009 Nov;2(6):581-3. doi: 10.1586/ecp.09.38.

No abstract available.

Cite
Kelleher P. AIDS vaccines: where are we?. Expert Rev Clin Pharmacol. 2009;2(6):581-3doi: 10.1586/ecp.09.38.
Kelleher, P. (2009). AIDS vaccines: where are we?. Expert review of clinical pharmacology, 2(6), 581-3. https://doi.org/10.1586/ecp.09.38
Kelleher, Peter. "AIDS vaccines: where are we?." Expert review of clinical pharmacology vol. 2,6 (2009): 581-3. doi: https://doi.org/10.1586/ecp.09.38
Kelleher P. AIDS vaccines: where are we?. Expert Rev Clin Pharmacol. 2009 Nov;2(6):581-3. doi: 10.1586/ecp.09.38. PMID: 22112252.
Copy Download .nbib Format: NLM
Development of human dendritic cells and their role in HIV infection: antiviral immunity versus HIV transmission.

Frontiers in microbiology

Tsunetsugu-Yokota Y, Muhsen M.
PMID: 23847602
Front Microbiol. 2013 Jul 09;4:178. doi: 10.3389/fmicb.2013.00178. eCollection 2013.

Although dendritic cells (DCs) represent a small cell population in the body, they have been recognized as professional antigen presenting cells and key players of both innate and acquired immunity. The recent expansion of basic knowledge concerning differentiation and...

Cite
Tsunetsugu-Yokota Y, Muhsen M. Development of human dendritic cells and their role in HIV infection: antiviral immunity versus HIV transmission. Front Microbiol. 2013;4:178doi: 10.3389/fmicb.2013.00178.
Tsunetsugu-Yokota, Y., & Muhsen, M. (2013). Development of human dendritic cells and their role in HIV infection: antiviral immunity versus HIV transmission. Frontiers in microbiology, 4178. https://doi.org/10.3389/fmicb.2013.00178
Tsunetsugu-Yokota, Yasuko, and Muhsen, Mahmod. "Development of human dendritic cells and their role in HIV infection: antiviral immunity versus HIV transmission." Frontiers in microbiology vol. 4 (2013): 178. doi: https://doi.org/10.3389/fmicb.2013.00178
Tsunetsugu-Yokota Y, Muhsen M. Development of human dendritic cells and their role in HIV infection: antiviral immunity versus HIV transmission. Front Microbiol. 2013 Jul 09;4:178. doi: 10.3389/fmicb.2013.00178. eCollection 2013. PMID: 23847602; PMCID: PMC3705168.
Copy Download .nbib Format: NLM
Using Mobile Technology (pMOTAR) to Assess Reactogenicity: Protocol for a Pilot Randomized Controlled Trial.

JMIR research protocols

Mngadi KT, Maharaj B, Duki Y, Grove D, Andriesen J.
PMID: 30282622
JMIR Res Protoc. 2018 Oct 03;7(10):e175. doi: 10.2196/resprot.9396.

BACKGROUND: Accurate safety monitoring in HIV vaccine trials is vital to eventual licensure and consequent uptake of products. Current practice in preventive vaccine trials, under the HIV Vaccine Trials Network (HVTN), is to capture related side effects in a...

Cite
Mngadi KT, Maharaj B, Duki Y, et al. Using Mobile Technology (pMOTAR) to Assess Reactogenicity: Protocol for a Pilot Randomized Controlled Trial. JMIR Res Protoc. 2018;7(10):e175doi: 10.2196/resprot.9396.
Mngadi, K. T., Maharaj, B., Duki, Y., Grove, D., & Andriesen, J. (2018). Using Mobile Technology (pMOTAR) to Assess Reactogenicity: Protocol for a Pilot Randomized Controlled Trial. JMIR research protocols, 7(10), e175. https://doi.org/10.2196/resprot.9396
Mngadi, Kathryn Therese, et al. "Using Mobile Technology (pMOTAR) to Assess Reactogenicity: Protocol for a Pilot Randomized Controlled Trial." JMIR research protocols vol. 7,10 (2018): e175. doi: https://doi.org/10.2196/resprot.9396
Mngadi KT, Maharaj B, Duki Y, Grove D, Andriesen J. Using Mobile Technology (pMOTAR) to Assess Reactogenicity: Protocol for a Pilot Randomized Controlled Trial. JMIR Res Protoc. 2018 Oct 03;7(10):e175. doi: 10.2196/resprot.9396. PMID: 30282622; PMCID: PMC6231778.
Copy Download .nbib Format: NLM
Ensuring Access to HIV Prevention Services in South African HIV Vaccine Trials: Correspondence Between Guidelines and Practices.

Public health ethics

Essack Z.
PMID: 25031609
Public Health Ethics. 2014 Jul;7(2):195-206. doi: 10.1093/phe/phu010.

Researchers and sponsors are required to assist HIV prevention trial participants to remain HIV-uninfected by ensuring access to prevention services. Ethics guidelines require that these HIV risk-reduction services be state of the art. This and related ethics recommendations have...

Cite
Essack Z. Ensuring Access to HIV Prevention Services in South African HIV Vaccine Trials: Correspondence Between Guidelines and Practices. Public Health Ethics. 2014;7(2):195-206doi: 10.1093/phe/phu010.
Essack, Z. (2014). Ensuring Access to HIV Prevention Services in South African HIV Vaccine Trials: Correspondence Between Guidelines and Practices. Public health ethics, 7(2), 195-206. https://doi.org/10.1093/phe/phu010
Essack, Zaynab. "Ensuring Access to HIV Prevention Services in South African HIV Vaccine Trials: Correspondence Between Guidelines and Practices." Public health ethics vol. 7,2 (2014): 195-206. doi: https://doi.org/10.1093/phe/phu010
Essack Z. Ensuring Access to HIV Prevention Services in South African HIV Vaccine Trials: Correspondence Between Guidelines and Practices. Public Health Ethics. 2014 Jul;7(2):195-206. doi: 10.1093/phe/phu010. PMID: 25031609; PMCID: PMC4097012.
Copy Download .nbib Format: NLM
Probing the possibilities for T-cell-based AIDS vaccines.

Current opinion in HIV and AIDS

Garber DA, Feinberg MB.
PMID: 19372827
Curr Opin HIV AIDS. 2006 Jul;1(4):314-22. doi: 10.1097/01.COH.0000232347.15909.22.

PURPOSE OF REVIEW: This review will discuss the current challenges facing the development of a successful AIDS vaccine and approaches being pursued to overcome them, with an emphasis on vaccines designed to elicit primarily cellular, rather than humoral, antiviral...

Cite
Garber DA, Feinberg MB. Probing the possibilities for T-cell-based AIDS vaccines. Curr Opin HIV AIDS. 2006;1(4):314-22doi: 10.1097/01.COH.0000232347.15909.22.
Garber, D. A., & Feinberg, M. B. (2006). Probing the possibilities for T-cell-based AIDS vaccines. Current opinion in HIV and AIDS, 1(4), 314-22. https://doi.org/10.1097/01.COH.0000232347.15909.22
Garber, David A, and Feinberg, Mark B. "Probing the possibilities for T-cell-based AIDS vaccines." Current opinion in HIV and AIDS vol. 1,4 (2006): 314-22. doi: https://doi.org/10.1097/01.COH.0000232347.15909.22
Garber DA, Feinberg MB. Probing the possibilities for T-cell-based AIDS vaccines. Curr Opin HIV AIDS. 2006 Jul;1(4):314-22. doi: 10.1097/01.COH.0000232347.15909.22. PMID: 19372827.
Copy Download .nbib Format: NLM
HIV/AIDS Vaccines: How long must humanity wait?.

Sultan Qaboos University medical journal

Al-Jabri AA.
PMID: 21748103
Sultan Qaboos Univ Med J. 2007 Dec;7(3):193-5.

No abstract available.

Cite
Al-Jabri AA. HIV/AIDS Vaccines: How long must humanity wait?. Sultan Qaboos Univ Med J. 2007;7(3):193-5
Al-Jabri, A. A. (2007). HIV/AIDS Vaccines: How long must humanity wait?. Sultan Qaboos University medical journal, 7(3), 193-5.
Al-Jabri, Ali A. "HIV/AIDS Vaccines: How long must humanity wait?." Sultan Qaboos University medical journal vol. 7,3 (2007): 193-5.
Al-Jabri AA. HIV/AIDS Vaccines: How long must humanity wait?. Sultan Qaboos Univ Med J. 2007 Dec;7(3):193-5. PMID: 21748103; PMCID: PMC3074885.
Copy Download .nbib Format: NLM
Towards an AIDS vaccine: challenges and prospects.

Immunology today

Homsy J, Steimer K, Kaslow R.
PMID: 25290421
Immunol Today. 1987;8(7):193-6. doi: 10.1016/0167-5699(87)90152-6.

Since the human immunodeficiency virus (HIV) started its spread through the human population, the AIDS epidemic has steadily increased on all continents unchecked by any therapeutic or preventive intervention, except for education. The search for an AIDS cure is...

Cite
Homsy J, Steimer K, Kaslow R. Towards an AIDS vaccine: challenges and prospects. Immunol Today. 1987;8(7):193-6doi: 10.1016/0167-5699(87)90152-6.
Homsy, J., Steimer, K., & Kaslow, R. (1987). Towards an AIDS vaccine: challenges and prospects. Immunology today, 8(7), 193-6. https://doi.org/10.1016/0167-5699(87)90152-6
Homsy, J, et al. "Towards an AIDS vaccine: challenges and prospects." Immunology today vol. 8,7 (1987): 193-6. doi: https://doi.org/10.1016/0167-5699(87)90152-6
Homsy J, Steimer K, Kaslow R. Towards an AIDS vaccine: challenges and prospects. Immunol Today. 1987;8(7):193-6. doi: 10.1016/0167-5699(87)90152-6. PMID: 25290421.
Copy Download .nbib Format: NLM
Be legally wise: When is parental consent required for adolescents' access to pre-exposure prophylaxis (PrEP)?.

Southern African journal of HIV medicine

Strode A, Slack CM, Essack Z, Toohey JD, Bekker LG.
PMID: 33240536
South Afr J HIV Med. 2020 Nov 10;21(1):1129. doi: 10.4102/sajhivmed.v21i1.1129. eCollection 2020.

BACKGROUND: South African adolescents (12-17 years) need an array of prevention tools to address their risk of acquiring the life-long, stigmatized condition that is HIV. Prevention tools include pre-exposure prophylaxis (PrEP). However, service providers may not be clear on...

Cite
Strode A, Slack CM, Essack Z, et al. Be legally wise: When is parental consent required for adolescents' access to pre-exposure prophylaxis (PrEP)?. South Afr J HIV Med. 2020;21(1):1129doi: 10.4102/sajhivmed.v21i1.1129.
Strode, A., Slack, C. M., Essack, Z., Toohey, J. D., & Bekker, L. G. (2020). Be legally wise: When is parental consent required for adolescents' access to pre-exposure prophylaxis (PrEP)?. Southern African journal of HIV medicine, 21(1), 1129. https://doi.org/10.4102/sajhivmed.v21i1.1129
Strode, Ann, et al. "Be legally wise: When is parental consent required for adolescents' access to pre-exposure prophylaxis (PrEP)?." Southern African journal of HIV medicine vol. 21,1 (2020): 1129. doi: https://doi.org/10.4102/sajhivmed.v21i1.1129
Strode A, Slack CM, Essack Z, Toohey JD, Bekker LG. Be legally wise: When is parental consent required for adolescents' access to pre-exposure prophylaxis (PrEP)?. South Afr J HIV Med. 2020 Nov 10;21(1):1129. doi: 10.4102/sajhivmed.v21i1.1129. eCollection 2020. PMID: 33240536; PMCID: PMC7669975.
Copy Download .nbib Format: NLM
Erratum.

Science (New York, N.Y.)

[No authors listed]
PMID: 17819210
Science. 1986 Jan 03;231(4733):10. doi: 10.1126/science.231.4733.10-d.

In an article by Colin Norman on research on AIDS vaccines, "AIDS virus presents moving target" (News and Comment, 20 Dec., p. 1357), it was stated that the official goal for getting a vaccine ready for general use has...

Cite
Erratum. Science. 1986;231(4733):10doi: 10.1126/science.231.4733.10-d.
(1986). Erratum. Science (New York, N.Y.), 231(4733), 10. https://doi.org/10.1126/science.231.4733.10-d
"Erratum." Science (New York, N.Y.) vol. 231,4733 (1986): 10. doi: https://doi.org/10.1126/science.231.4733.10-d
Erratum. Science. 1986 Jan 03;231(4733):10. doi: 10.1126/science.231.4733.10-d. PMID: 17819210.
Copy Download .nbib Format: NLM
[No title available]

South African journal of bioethics and law

Strode AE, Toohey J, Singh P, Slack CM.
PMID: 29887972
S Afr J Bioeth Law. 2015;8(1):22-25. doi: 10.7196/SAJBL.346. Epub 2015 May 15.

Consent is required for almost all health research. In order for consent to be valid a number of requirements must be met including that the consent cannot be

Cite
Strode AE, Toohey J, Singh P, et al. . S Afr J Bioeth Law. 2015;8(1):22-25doi: 10.7196/SAJBL.346.
Strode, A. E., Toohey, J., Singh, P., & Slack, C. M. (2015). . South African journal of bioethics and law, 8(1), 22-25. https://doi.org/10.7196/SAJBL.346
Strode, A E, et al. "." South African journal of bioethics and law vol. 8,1 (2015): 22-25. doi: https://doi.org/10.7196/SAJBL.346
Strode AE, Toohey J, Singh P, Slack CM. . S Afr J Bioeth Law. 2015;8(1):22-25. doi: 10.7196/SAJBL.346. Epub 2015 May 15. PMID: 29887972; PMCID: PMC5990274.
Copy Download .nbib Format: NLM
Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions.

Current infectious disease reports

Mulligan MJ.
PMID: 19698284
Curr Infect Dis Rep. 2009 Sep;11(5):399-406. doi: 10.1007/s11908-009-0056-9.

Nearly three decades after the first description in 1981 of the syndrome eventually designated as AIDS, only five efficacy trials testing just three HIV vaccine concepts have been initiated. In 2007, an efficacy analysis was conducted for the first...

Cite
Mulligan MJ. Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions. Curr Infect Dis Rep. 2009;11(5):399-406doi: 10.1007/s11908-009-0056-9.
Mulligan, M. J. (2009). Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions. Current infectious disease reports, 11(5), 399-406. https://doi.org/10.1007/s11908-009-0056-9
Mulligan, Mark J. "Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions." Current infectious disease reports vol. 11,5 (2009): 399-406. doi: https://doi.org/10.1007/s11908-009-0056-9
Mulligan MJ. Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions. Curr Infect Dis Rep. 2009 Sep;11(5):399-406. doi: 10.1007/s11908-009-0056-9. PMID: 19698284.
Copy Download .nbib Format: NLM
The challenge of testing potential AIDS vaccines.

Science (New York, N.Y.)

Barnes DM.
PMID: 17756865
Science. 1986 Sep 12;233(4769):1151. doi: 10.1126/science.233.4769.1151.

No abstract available.

Cite
Barnes DM. The challenge of testing potential AIDS vaccines. Science. 1986;233(4769):1151doi: 10.1126/science.233.4769.1151.
Barnes, D. M. (1986). The challenge of testing potential AIDS vaccines. Science (New York, N.Y.), 233(4769), 1151. https://doi.org/10.1126/science.233.4769.1151
Barnes, D M. "The challenge of testing potential AIDS vaccines." Science (New York, N.Y.) vol. 233,4769 (1986): 1151. doi: https://doi.org/10.1126/science.233.4769.1151
Barnes DM. The challenge of testing potential AIDS vaccines. Science. 1986 Sep 12;233(4769):1151. doi: 10.1126/science.233.4769.1151. PMID: 17756865.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries